Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Evans

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 19, 2012
What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetesChristopher Ll Morgan, Chris D Poole, Marc Evans, et al.
Clinical Kidney Journal|April 4, 2022
Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database studyGlen James, Jennifer Kim, Carl Mellström, et al.
BMC Nephrology|August 24, 2018
Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalinkHans Furuland, Phil McEwan, Marc Evans, et al.
ESC Heart Failure|January 11, 2019
Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UKCecilia Linde, Lei Qin, Ameet Bakhai, et al.
Journal of Medical Economics|November 23, 2017
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulinMarc Evans, Liana K Billings, Jonas Håkan-Bloch, et al.
Infection and Immunity|March 24, 2010
Association of pathogen strain-specific gene transcription and transmission efficiency phenotype of Anaplasma marginaleJoseph T Agnes, David Herndon, Massaro W Ueti, et al.
Advances in Therapy|January 12, 2021
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature ReviewOliver Darlington, Carissa Dickerson, Marc Evans, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 27, 2025
Practical Approaches to Continuous Glucose Monitoring in Primary Care: A UK-Based Consensus OpinionKevin Fernando, Vicki Alabraba, John B Welsh, et al.
Patient Preference and Adherence|October 3, 2013
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspectiveStewart B Harris, Kamlesh Khunti, Mona Landin-Olsson, et al.
Biochemical and Biophysical Research Communications|June 14, 2005
The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calciumNeenu Singh, Richard Webb, Rachel Adams, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
The Journal of Clinical Endocrinology and Metabolism|October 19, 2012
What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetesChristopher Ll Morgan, Chris D Poole, Marc Evans, et al.
Clinical Kidney Journal|April 4, 2022
Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database studyGlen James, Jennifer Kim, Carl Mellström, et al.
BMC Nephrology|August 24, 2018
Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalinkHans Furuland, Phil McEwan, Marc Evans, et al.
ESC Heart Failure|January 11, 2019
Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UKCecilia Linde, Lei Qin, Ameet Bakhai, et al.
Journal of Medical Economics|November 23, 2017
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulinMarc Evans, Liana K Billings, Jonas Håkan-Bloch, et al.
Infection and Immunity|March 24, 2010
Association of pathogen strain-specific gene transcription and transmission efficiency phenotype of Anaplasma marginaleJoseph T Agnes, David Herndon, Massaro W Ueti, et al.
Advances in Therapy|January 12, 2021
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature ReviewOliver Darlington, Carissa Dickerson, Marc Evans, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 27, 2025
Practical Approaches to Continuous Glucose Monitoring in Primary Care: A UK-Based Consensus OpinionKevin Fernando, Vicki Alabraba, John B Welsh, et al.
Patient Preference and Adherence|October 3, 2013
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspectiveStewart B Harris, Kamlesh Khunti, Mona Landin-Olsson, et al.
Biochemical and Biophysical Research Communications|June 14, 2005
The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calciumNeenu Singh, Richard Webb, Rachel Adams, et al.
Pageof 16